ONCOLYTICS BIOTECH INC (ONCY)
$0.85+$0.00 (+0.31%) Today
Wayne Pisano - DirectorOncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
https://www.oncolyticsbiotech.comSEC filings for ONCY on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 14 | 2,246,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
26 Form 4 filings on record, the earliest from Jan 20, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Wayne Pisano - Director | Grant or award | Stock Option | 30,000 | $0.00 | - | |
| Jonathan Rigby - Director | Grant or award | Stock Option | 30,000 | $0.00 | - | |
 Angela Holtham - Director | Grant or award | Stock Option | 30,000 | $0.00 | - | |
| James T. Parsons - Director | Grant or award | Stock Option | 30,000 | $0.00 | - | |
| Kirk Look - Officer | Grant or award | Stock Option | 260,000 | $0.00 | - | |
| Andrew Aromando - Officer | Grant or award | Stock Option | 260,000 | $0.00 | - | |
| Jared Kelly - Officer | Grant or award | Stock Option | 755,000 | $0.00 | - | |
| Patricia S. Andrews - Director | Grant or award | Stock Option | 30,000 | $0.00 | - | |
| Bernd R. Seizinger - Director | Grant or award | Stock Option | 30,000 | $0.00 | - | |
| Allison Hagerman - Officer | Grant or award | Stock Option | 260,000 | $0.00 | - | |
| Deborah Margaret Brown - Director | Grant or award | Stock Option | 30,000 | $0.00 | - | |
| Thomas Charles Heineman - Officer | Grant or award | Stock Option | 260,000 | $0.00 | - | |
| John Bearden McAdory - Officer | Grant or award | Stock Option | 145,000 | $0.00 | - | |
| Stephen C. Glover - Director | Grant or award | Stock Option | 96,000 | $0.00 | - | |
| James T. Parsons - Director | Open-market purchase | Common Shares | 10,000 | $1.03 | $10K | |
| Jared Kelly - Officer | Open-market purchase | Common Shares | 5,050 | $0.96 | $5K | |
| Jared Kelly - Officer | Open-market purchase | Common Shares | 5,600 | $0.84 | $5K | |
| Jared Kelly - Officer | Open-market purchase | Common Shares | 29,500 | $0.84 | $25K | |
| Kirk Look - Officer | Open-market purchase | Common Shares | 12,000 | $0.84 | $10K | |
| Wayne Pisano - Director | Open-market purchase | Common Shares | 30,000 | $0.84 | $25K | |
| Thomas Charles Heineman - Officer | Open-market purchase | Common Shares | 12,132 | $0.83 | $10K | |
| Deborah Margaret Brown - Director | Open-market purchase | Common Shares | 25,000 | $0.85 | $21K | |
| Allison Hagerman - Officer | Open-market purchase | Common Shares | 10,000 | $0.83 | $8K | |
| Bernd R. Seizinger - Director | Open-market purchase | Common Shares | 60,000 | $0.83 | $50K | |
| Bernd R. Seizinger - Director | Open-market purchase | Common Shares | 40,000 | $0.85 | $34K | |
| Andrew Aromando - Officer | Open-market purchase | Common Shares | 29,600 | $0.86 | $25K | |
| Patricia S. Andrews - Director | Open-market purchase | Common Shares | 35,400 | $0.86 | $30K | |
| Bernd R. Seizinger - Director | Open-market purchase | Common Shares | 100,000 | $1.04 | $104K |
ONCOLYTICS BIOTECH INC (ONCY) had 14 insider filings in the last 90 days, with the most recent on 2026-06-03. The full record for ONCY runs to 26 Form 4 filings, the earliest from 2026-01-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ONCY were filed in the last 90 days. 14 purchases are on record for this company.
No insider sales of ONCY were filed in the last 90 days.
This page tracks ONCY Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ONCY to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
